Collier, K.A., Valencia, H., Newton, H., et al. (2021) A Phase 1 Trial of the Histone Deacetylase Inhibitor AR-42 in Patients with Neurofibromatosis Type 2-Associated Tumors and Advanced Solid Malignancies. Cancer Chemotherapy and Pharmacology, 87, 599-611.
https://doi.org/10.1007/s00280-020-04229-3

has been cited by the following article:

• TITLE: Recent Advances in Metabolomics and Therapeutics for Cancer Cachexia

  AUTHORS: Charles Paul Lambert

  KEYWORDS: Drug Discovery, Stable Isotopes, Muscle Wasting, Oncology

  JOURNAL NAME: Journal of Cancer Therapy, Vol.14 No.1, January 19, 2023

  ABSTRACT: Cancer Cachexia afflicts 50 - 80 percent of cancer patients with roughly 20 percent of all cancer patients dying of cachexia. Metabolomics is the study of different metabolites, their location in the body, and the timing of their appearance and disappearance. As a result, this science of Metabolomics can be applied to solve the problem of Cancer Cachexia. In this review, I examine recent studies on metabolism that use Metabolomics as their instrument of discovery. Further, this review details potential therapeutic interventions at the cellular, animal, and human level that show promise for attenuating Cancer Cachexia.